PDCD1 and pancreatic neoplasm: We have recently shown that OBP-702 enhanced the anti-tumor efficacy of anti-programmed cell death 1 antibody (anti-PD-1 Ab) in a syngeneic mouse model of pancreatic cancer via the enhancement of ICD and CD8+ T cell infiltration into tumors.33